1E M de Villiers,Heterogeneity of the human papillomavirus group.J Virol.,1989,63(11):4898-4903.
2Bosch FX,M.M.,Munoz N,et al.,Prevalence of human papillomavirus in cervical cancer:A worldwide perspective.International biological study on cervical cancer (IBSCC) Study Group [ see comments].J Natl Cancer Inst,1995,87:796-802.
3Bosch FX,A.L.,N Munoz,et al.,The causal relation between human papilloma-virus and cervical cancer.J.Clin.Pathol.,2002,55:244-265.
4Bosch FX,N.M.o.,The viral etiology of cervical cancer.Virus Research,2002,89:183-190.
5ZurHausen H,Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types.,in Human pathogenic papillomaviruses.,z.H,Editor.1994,Springer Verlag:Heidelberg.131-6.
6Zur Hausen H,Papillomaviruses and cancer:from basic studies to clinical application.Nat Rev Cancer,2002,2:342-50.
7Romanczuk H,H.P.,Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortal ization capacity.Proc Natl Acad Sci USA,1992,89(7):3159-3163.
8Schiffman MH,New epidemiology of human papillomavirus infec tion and cervical neoplasia.J Natl Cancer Inst,1999,87:1345-47.
9Denise A Galloway,Papillomavirus vaccines in clinical trials.Lancet Infect,2003,3:469-75.
10Sillman FH,S.S.,Shaffer D.,Ano-genital neoplasia in renal trans-plant patients.Ann Transplant,1997,2:59-66.
